Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Rating of “Buy” from Analysts

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) have received an average rating of “Buy” from the seven brokerages that are currently covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have covered the stock in the last year is $21.00.

Several research analysts recently issued reports on the company. Citigroup initiated coverage on Olema Pharmaceuticals in a research report on Tuesday, January 30th. They set a “buy” rating and a $20.00 target price on the stock. Capital One Financial restated an “overweight” rating on shares of Olema Pharmaceuticals in a report on Thursday, February 22nd.

Insider Buying and Selling at Olema Pharmaceuticals

In other news, Director Cyrus Harmon sold 25,000 shares of the stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $12.41, for a total value of $310,250.00. Following the sale, the director now owns 846,283 shares in the company, valued at $10,502,372.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 23.50% of the company’s stock.

Institutional Trading of Olema Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in Olema Pharmaceuticals by 58.2% in the fourth quarter. Vanguard Group Inc. now owns 2,705,895 shares of the company’s stock valued at $37,964,000 after acquiring an additional 995,588 shares during the period. BlackRock Inc. lifted its stake in shares of Olema Pharmaceuticals by 11.1% in the 1st quarter. BlackRock Inc. now owns 2,552,949 shares of the company’s stock valued at $10,874,000 after purchasing an additional 254,785 shares during the period. Vivo Capital LLC boosted its holdings in Olema Pharmaceuticals by 39.9% during the third quarter. Vivo Capital LLC now owns 1,873,704 shares of the company’s stock worth $23,140,000 after buying an additional 534,433 shares in the last quarter. MPM Bioimpact LLC boosted its holdings in Olema Pharmaceuticals by 301.7% during the third quarter. MPM Bioimpact LLC now owns 1,857,681 shares of the company’s stock worth $22,942,000 after buying an additional 1,395,181 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Olema Pharmaceuticals by 1.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,715,420 shares of the company’s stock valued at $24,069,000 after buying an additional 21,420 shares during the period. 91.78% of the stock is owned by institutional investors and hedge funds.

Olema Pharmaceuticals Trading Up 1.1 %

Shares of OLMA stock opened at $11.32 on Friday. Olema Pharmaceuticals has a 12-month low of $3.00 and a 12-month high of $17.79. The business’s fifty day simple moving average is $13.17 and its 200-day simple moving average is $13.12. The company has a market cap of $633.01 million, a PE ratio of -5.24 and a beta of 2.13.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1b/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer.